Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5915-5922

  Zhang, Yujian ^a   Chertov, Oleg ^b   Zhang, Jingli ^a   Hassan, Raffit ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; CAMOSTAT; DISINTEGRIN; EPIDERMAL GROWTH FACTOR; IMMUNOTOXIN; IMMUNOTOXIN SS1P; MARIMASTAT; MATRIX METALLOPROTEINASE; MESOTHELIN; MONOCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CYTOTOXICITY; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG CANCER; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYTOTOXINS; EPIDERMAL GROWTH FACTOR; GPI-LINKED PROTEINS; HUMANS; MESOTHELIOMA; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 80052190561     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0466     Document Type: Article

References (34)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40. (Pubitemid 26041483)
2. Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer 1994;57:90-7. (Pubitemid 24117106)
3. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28. (Pubitemid 37315193)
4. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7. (Pubitemid 36337423)
5. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9. (Pubitemid 47502082)
6. Kreitman RJ, Hassan R, FitzGerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
7. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701. (Pubitemid 44297823)
8. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007;13:7166-71. (Pubitemid 350276903)
9. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal anti-body MORAb-009 in patients with mesothelin expressing cancers. Clin Cancer Res 2010;16:6132-8.
10. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70:9053-61.
11. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
12. Leao IC, Ganesan P, Armstrong TD, Jaffee EM. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci2008;1:228-39.
13. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010;70:109-18.
14. Hung CF, Tsai YC, He L, Wu TC. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther 2007;14:921-9. (Pubitemid 46865503)
15. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6. (Pubitemid 37443528)
16. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6. (Pubitemid 29487415)
17. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 2010;70:1082-9.
18. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007;104:17099-104. (Pubitemid 350210998)
19. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20. (Pubitemid 43823532)
20. Chatterjee S, Mayor S. The GPI-anchor and protein sorting. Cell Mol Life Sci 2001;58:1969-87. (Pubitemid 34016972)
21. Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008;99:590-4. (Pubitemid 351228578)
22. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010;1803:55-71.
23. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 2009;15:2319-35.
24. Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006;312:3969-80. (Pubitemid 44828045)
25. Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J. Posttranscriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem 2007;282:8325-31. (Pubitemid 47093613)
26. GPI Lipid Anchor Project. Available from: http://mendel.imp.ac.at/gpi/ gpi-server.html [accessed 2011 Feb 25].
27. Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 2001;276:37743-6.
28. Esselens CW, Malapeira J, Colomé N, Moss M, Canals F, Arribas J. Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem 2008;389:1075-84.
29. von Tresckow B, Kallen KJ, von Strandmann EP, Borchmann P, Lange H, Engert A, et al. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 2004;172:4324-31. (Pubitemid 38375247)
30. Thiel KW, Carpenter G. ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains. Biochem Biophys Res Commun 2006;350:629-33. (Pubitemid 44550203)
31. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003;22:1114-24. (Pubitemid 36313595)
32. Troeberg L, Fushimi K, Khokha R, Emonard H, Ghosh P, Nagase H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 2008;22:3515-24.
33. Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 2007;13:2087-100. (Pubitemid 47040490)
34. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50. (Pubitemid 44018087)